Alterations in biochemical parameters associated with kidney disease at a global level (Original)
Keywords:
Kidneys; biochemistry; alterations; renal dysfunctionAbstract
Kidney disease is a progressive and incurable pathology, in addition to having high morbidity and mortality, which generally occurs in the adult population. Silent in its initial stages, but with a progressive course, it leads in the absence of adequate treatment to advanced chronic kidney disease and kidney failure, which necessarily leads the patient to replacement therapy, be it chronic dialysis or kidney transplant. The objective was to determine the alterations in biochemical parameters associated with kidney disease globally. The methodology was a descriptive, documentary design. The results highlight that the prevalence of this pathology is not as high as many other investigations indicate, since these were between 1.7% and 26.80%, with the exception of Canada in 2021, since the frequency was 47.9%. Regarding biochemical alterations, among the most common were Cystatin C and creatinine, in addition, alterations in glucose, triglycerides, cholesterol were presented. This concludes that, despite being a very common pathology and one of the first worldwide, not all countries have a high prevalence of kidney disease, however, it causes alterations in the biochemical parameters of people who suffer from it, causing it to evolve over time.
Downloads
References
Al Vrijlandt, W., de Jong, M., Prins, J., Bramham, K., Vrijlandt, P., Janse, R., . . . Carrero, J. (2023). Prevalence of chronic kidney disease in women of reproductive age and observed birth rates. Journal of Nephrology, 36, 1341–1347. https://link.springer.com/article/10.1007/s40620-022-01546-z
Ávila-Jalca, M., & Mina-Ortiz, J. (2023). Cistatina-C y etapas de daño renal en adultos de un laboratorio privado, ciudad de Jipijapa. Journal Scientific MQRInvestigar, 7(4), 294-2308. doi: https://doi.org/10.56048/MQR20225.7.4.2023.2294-2308.
Ávila-Rosales, D., Curbelo-Rodríguez, A., & Ramos-Rodríguez, C. (2022). Determinación de cistatina C para evaluación del filtrado glomerular en fases predialíticas de la enfermedad renal crónica. Revista Archivo Médico de Camagüey, 26. http://scielo.sld.cu/scielo.php?pid=S1025-02552022000100040&script=sci_arttext&tlng=en
Brookes y Power. (2022). Elevated serum urea-to-creatinine ratio is associated with adverse inpatient clinical outcomes in non-end stage chronic kidney disease. Scientific Reports, 12(10827). https://www.nature.com/articles/s41598-022-25254-7
Cha'on, U., Tippayawat, P., Sae-ung, N., Pinlaor, P., Sirithanaphol, W., Theeranut, A., . . . Anutrakulchai, S. (2022). High prevalence of chronic kidney disease and its related risk factors in rural areas of Northeast Thailand. Scientific Reports, 12(18188). https://www.nature.com/articles/s41598-022-22538-w
Chu, L., Fuller, M., Jervis, K., Ciaccia, A., & Abirbol, A. (2021). Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Clinical Therapeutics, 43(9), 1558-1573. doi: https://doi.org/10.1016/j.clinthera.2021.07.015.
Dai, Y., Quan, J., Xiong, L., Luo, Y., & Yi, B. (2022). Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis. Renal Failure, 44(1), 862-880. doi: https://doi.org/10.1080/0886022X.2022.2079522.
Dehghani, A., Alishavandi, S., Nourimajalan, N., Fallahzadeh, H., & Rahmanian, V. (2022). Prevalence of chronic kidney diseases and its determinants among Iranian adults: results of the first phase of Shahedieh cohort study. BMC Nephrology, 23(203). https://link.springer.com/article/10.1186/s12882-022-02832-5
Delgado, C., & Tapia, M. (2022). Estudio observacional de Cistatina C como marcador temprano de Enfermedad Renal Crónica en pacientes pediátricos del Hospital Pediátrico Baca Ortiz en el período enero–diciembre del 2021. Quito : UCE. https://www.dspace.uce.edu.ec/entities/publication/f16b0f82-997c-41ce-a3de-10b7c85d674a
Espinoza, G., Julián, Y., López, M., & Berumen, M. (2022). Screening de enfermedad renal crónica en pacientes diabéticos de larga evolución de la UMF (unidad de medicina familiar) 222. Rev. colom. nefrol, 9(1). http://www.scielo.org.co/scielo.php?pid=S2500-50062022000100203&script=sci_arttext
Kalantar, et, al. (2021). Chronic kidney disease. Seminar, 398(10302). https://scholar.google.es/citations?user=kYonxxoAAAAJ&hl=es&oi=sra
Legton, et, al. (2023). Cistatina c, urea y creatinina como indicador pronóstico de daño renal. Journal Scientific MQRInvestigar, 7(3), 28-646 . doi: https://doi.org/10.56048/MQR20225.7.3.2023.628-646.
Llisterri, J., Micó-Pérez, R., Velilla-Zancada, S., Rodríguez-Roca, G., Prieto-Díaz, M., Martín-Sánchez, V., . . . Cinza-Sanjurjo, S. (2021). Prevalencia de la enfermedad renal crónica y factores asociados en la población asistida en atención primaria de España: resultados del estudio IBERICAN. Medicina Clínica, 156(4), 157-165. doi: https://doi.org/10.1016/j.medcli.2020.03.005.
Martínez, G., Guerra, E., & Pérez, D. (2020). Enfermedad renal crónica, algunas consideraciones actuales. Revista Médica Multimed, 24(2). http://scielo.sld.cu/scielo.php?pid=S1028-48182020000200464&script=sci_arttext
McRae, C., Mercer, S., Guthrie, B., & Henderson, D. (2021). Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. British Journal of General Practice, 71(704), e243-e249. doi: https://doi.org/10.3399/bjgp20X714125.
Meena, B., Kumar, M., & Kale, S. (2022). Hyperlipidemia in patients with chronic kidney disease on hemodialysis/conservative management. National Journal of Physiology, Pharmacy and Pharmacology, 13(02). https://www.researchgate.net/profile/Bhagwan-Meena-
Nagai, K., Asahi, K., Iseki, K., & Yamagata, K. (2021). Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clinical and Experimental Nephrology, 25, 885–892. https://link.springer.com/article/10.1007/s10157-021-02049-0
Noels, H., Lehrke, M., Vanholder, R., & Jankowski, J. (2021). Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nature Reviews Nephrology, 17, 528–542. https://www.nature.com/articles/s41581-021-00423-5
Pérez, R., Oldano, A., Ávila, M., & Luciardi, H. (2020). Marcadores bioquímicos en la detección y estadificación del riesgo de progresión de la enfermedad renal crónica. Acta bioquím. clín. latinoam, 54(4). http://www.scielo.org.ar/scielo.php?pid=S0325-29572020000400383&script=sci_arttext&tlng=en
Rizwan, M., Taha, M., Maqsood, A., & Mukhtar, T. (2021). A Study of Lipid Profile in Chronic Kidney Disease Patients . P J M H S, 15(9). https://scholar.google.es/citations?user=Og-E9koAAAAJ&hl=es&oi=sra
Published
Issue
Section
License
Copyright (c) 2025 Roca. Scientific-educational publication of Granma province.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
